Cohn Amy C, Toomes Carmel, Potter Catherine, Towns Katherine V, Hewitt Alex W, Inglehearn Chris F, Craig Jamie E, Mackey David A
Ocular Diagnostic Clinic, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Am J Ophthalmol. 2007 Apr;143(4):656-62. doi: 10.1016/j.ajo.2006.12.038. Epub 2007 Feb 15.
We identified families with autosomal dominant optic atrophy (ADOA), determined the number and type of OPA1 mutations, and investigated the phenotypic variation and penetrance in ADOA Australian pedigrees.
Cross-sectional genetics study.
Probands were identified on the basis of characteristic clinical features of ADOA. We screened the OPA1 gene using single-strand conformational polymorphism, heteroduplex analysis (SSCP/HA), or by direct sequencing. Penetrance for pedigrees in which a mutation of OPA1 had been identified was calculated initially using all recruited individuals, and subanalysis was performed using only those families for which there was total recruitment of siblings.
A total of 406 patients from 17 pedigrees were recruited, and OPA1 mutations were identified in 11/17 (65%) of these. The mean age at clinical examination was 38.2 +/- 19.9 years (median age, 35 years; range, four to 83 years). The median best-corrected visual acuity in OPA1-mutation carriers was 20/70 (range, 20/16 to hand movements [HM]). The penetrance in Australian ADOA pedigrees in the families with complete sibling recruitment was 82.5%. On the other hand, overall penetrance for all individuals harboring an OPA1 mutation was 88%.
OPA1 mutations were identified in 11/17 (65%) of the ADOA pedigrees in this study. The penetrance in our cohort was lower than originally described (82.5% vs 98%) but higher than some recent studies since the availability of genotyping. It is anticipated that this figure would be even lower as more asymptomatic individuals are identified. There are likely to be other genetic and environmental modifiers influencing disease penetrance.
我们识别出常染色体显性遗传性视神经萎缩(ADOA)家系,确定OPA1突变的数量和类型,并研究澳大利亚ADOA家系中的表型变异和外显率。
横断面遗传学研究。
根据ADOA的特征性临床特征识别先证者。我们使用单链构象多态性、异源双链分析(SSCP/HA)或直接测序对OPA1基因进行筛查。对于已识别出OPA1突变的家系,最初使用所有招募的个体计算外显率,并仅对同胞全部被招募的那些家系进行亚分析。
共招募了来自17个家系的406例患者,其中11/17(65%)识别出OPA1突变。临床检查时的平均年龄为38.2±19.9岁(中位年龄35岁;范围4至83岁)。OPA1突变携带者的最佳矫正视力中位数为20/70(范围20/16至手动[HM])。同胞全部被招募的澳大利亚ADOA家系的外显率为82.5%。另一方面,所有携带OPA1突变个体的总体外显率为88%。
本研究中11/17(65%)的ADOA家系识别出OPA1突变。我们队列中的外显率低于最初描述的(82.5%对98%),但高于基因分型可用以来的一些近期研究。预计随着更多无症状个体被识别,这一数字会更低。可能存在其他影响疾病外显率的遗传和环境修饰因素。